Member Info for crumbs

I'd say the pressure is on...

And hasi has gone no emotion or argie bargie involved he's driven out in his Rolls Royce that of course, he will not hold on to for long :)

You just know he will cover the first jab of the Nottingham ( scancell ) vaccine...

'But instead of relying on jabs based on the spike protein, which mutates so fast, we need vaccines with some in-built insurance against the evolving virus.

I've covered the work of scientists in Nottingham who are trying to do just that. And the government has recently done a deal with a company called CureVac to make a more future-proof vaccine.

Until such a vaccine is available, re-starting normal, quarantine-free international travel is risky.

However much we all want a foreign holiday after a year of lockdowns, the virus won't stop evolving just to give us a break.'
https://news.sky.com/story/covid-19-this-virus-will-keep-evolving-and-that-makes-international-travel-risky-12232682

The viewing figure is having a gradual rise WF now over 200 viewers when it began the weekend barely over 100 and to me seems maybe from US viewers.... again IMHO this presentation has something to do with redmile... anyways market never lies so we'll see what impact it has haha

Fair enough.

hasiba you're only playing the covidity ball? ....
I reckon ph1 covidity trial will be Nottingham based myself

But definitely not to VAL!

I'm handing it over to VAR :)

The dreamers still on the pitch and the investors left with 'their ball' :)

All good fun and well another week ahead...
On re -viewing the Vox presentation, I think it is possibly redmile initiated.....

'In recent years, antibodies have become the best-selling drugs in the pharmaceutical market and have been approved for treating various human diseases, including many cancers, autoimmune, metabolic and infectious diseases. The global therapeutic monoclonal antibody market is estimated to be US$150 billion in 2019 and predicted to grow to US$300 billion by 2025.2



The ability to increase the potential therapeutic properties of any antibody would therefore be seen as highly advantageous. Scancell has used its AvidiMab™ technology to increase the avidity of its TaG antibodies, and these are currently being evaluated for the treatment of cancer. They are also being developed as antibody-drug conjugates (ADC).3



Professor Lindy Durrant, Chief Scientific Officer of Scancell and Corresponding Author, commented:

June 2020

"We are pleased to have our work published in the prestigious, peer reviewed journal, Cancer Research. Our AvidiMab™ technology increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification also causes direct killing of cancer cells by our glycan targeting antibodies, and therefore we believe this technology has the ability to create superior candidates for cancer immunotherapy."'

Nov 2020

'The peer-reviewed paper has resulted in a number of enquiries from international bodies and larger
developers considering licencing opportunities for application with their own antibodies.'

1) It wasn't really more technical than previous presentations basically there is now so much to cram in that, yes a lot can go woosh over heads... Cliff did add values the markets we are in referenced Keytruda... $150 billion MaBs market etc... pointed out Tear sold his company for over $2 billion so... supposed aimed at all... the viewing figures for the vid seemed to jump up by 70 views in a very short time from Yesterdays 100 odd views...

2) I don't know about that one... funny business we both witnessed there with trades going straight to negotiated... anyways only the seller knows what for and yes small amount of their holding ...

3)Agree short notice seems to be to do with Turner Pope...

4) Not a given but-expected lol off the Cliff we go:)

5) I'm supposing they still are with proactive? but dunno

yes, you are low on meds :) hope you are well though and guess we are very more in wait in see situ.. I think you should give the presentation a viewing but just remember that is all it is an up to date scancell presentation done by Cliff who is not Hollywood star material but did a decent job.

'For Dr. Robert Gallo, who co-discovered that HIV was the cause of AIDS and developed the HIV blood test, for a new vaccine to be next-generational, it must take a different approach than using the SARS-CoV-2 virus's mRNA to tell the body's cells to produce the virus's distinctive spike protein. That protein triggers the immune system to produce an immune response against SARS-CoV-2.

"For me, next-generational will be vaccines that are proven to be broader -- better able to cover spike mutations, if we rely only on attacking the spike," said Gallo, co-founder and director of the Institute of Human Virology at the University of Maryland School of Medicine, and co-founder and scientific advisor of the Global Virus Network.

"So, next-generation (vaccines) might be still attacking the spike but with greater breadth and maybe greater duration, however that is achieved. Alternatively, a second-generation (vaccine) might be still attacking the spike, but with a broader and more potent T cellular response," he added.

Another protein to consider, Gallo indicated, is the nucleocapsid, which, like the spike protein, is a structural protein found in the virus. "I suggest it because it might add to the T cell immune response," he explained.'

Hmmm... yes
https://www.scienceboard.net/index.aspx?sec=ser&sub=def&pag=dis&ItemID=2172

The Argentinian strategy :) well, it has won world cups ...

Anyways we are not at ph1 yet so...

Foxgate :)
I dunno.. And I don't really care either... if it is a fabrication the real naughty bit is using the good prof Pete James's name...
apart from that wouldn't influence my investment strategy here ...We have had people coming on here going on about deal revealing emails from Lindy in the past

I'm expecting an RNS sooner too...

When would I expect the earliest time for a pharma to show its face... once we know we have a clinically viable vaccine... by SKY report that was not quite where we were GMP needs to be done and then once it is shown to be up to standard and delivery is finalised etc ... all systems go...
You may get from Cliff we are not even looking to partner till after ph1... this IMHO is not the case at all!

'Scancell is calling for more funding to progress its new vaccine through clinical trial - hoping for a large pharmaceutical partner and investment of hundreds of millions of pounds.

Dr O'Bryan-Tear was optimistic the vaccine could be developed within a year - pointing to a similar timeframe for the first Covid jabs.

He said: "There is no reason why, if we get a partner, we shouldn't be able to do it as quickly as the others have done it."

The doctor added: "I think the pandemic will be around for two or three more years, because of supply, because of not being able to vaccinate developing countries.

"During that time, the virus will mutate, so there are plenty of opportunities for new entrants to try their hand.”

Who's upset? I think the issue was about running ph1's alone not about an investment strategy

'Dr Gillies O’Bryan-Tear: “I worked at GSK Biologicals in 2001-2002 leading the global clinical development of their paediatric vaccines. I currently work in a part-time capacity for Scancell Ltd, a company developing cancer vaccines and a Covid vaccine.”

expert reaction to Sanofi and GSK delaying their adjuvanted recombinant protein-based COVID-19 vaccine programme due to insufficient immune response in older adults
Sanofi and GSK have announced a delay in their adjuvanted recombinant protein-based COVID-19 vaccine programme to improve immune response in the elderly.



Dr Gillies O’Bryan-Tear, Chair, Policy and Communications, Faculty of Pharmaceutical Medicine, said:

“It is disappointing that the GSK/Sanofi Covid vaccine, coming as it does from one of the power houses of vaccine science in the world, has not performed as well as hoped for in the phase 2 study: the immune responses in older people were insufficient to take the programme forward in its current form. GSK and Sanofi are working towards a new trial with an improved antigen formulation.

“It is a setback in the world’s efforts to control the pandemic, but underlies the importance – as attested to by Kate Bingham and the UK Vaccines Task Force this week – of having multiple options in addressing this pandemic. It also reminds us that pharma research is high risk and not always successful immediately. Fortunately technology platforms such as the mRNA/Oxford vaccines appear to have shown good results thus far which underlines the importance of many companies, large and small, using their expertise and continuing to innovate in this space. We have been extremely fortunate to have seen successful results from at least 4 vaccines to date, with more coming, and it’s important to acknowledge the scale of this achievement in such a short time.

“The platform being used by Sanofi/GSK is an older technology which relies on adjuvanting of the vaccine material to induce an adequate immune response. Older adults are known to have lower immune responses to such vaccines and this may be overcome by either repeated injections (prime- boost approach) or by increasing the antigen dose within each shot. In this case the companies seem to have decided to increase the antigen dose within the shot. The revised protocol is scheduled to start in February and will include a comparison to a different vaccine. This can then take advantage of the measured immune response to predict potential for clinical efficacy. Indeed, as more data is delivered on the relationship between immune response and clinical effect, it should be possible to move from requiring large scale clinical efficacy trials towards the use of ‘immune correlates’ of protection to decrease time required to bring a vaccine made using well established technologies to the market.”

But surely this problem is being addressed now......we can only know if after or indeed pre ph1 nowt comes......risk/reward still in full on play here.

C7 it is now on the tube for your viewing pleasure...
https://www.youtube.com/watch?v=j80CDhunTAE&t=10s

It seems to have had a little surge in viewers since yesterday.....

It is what it is and was and is ... A presentation of where scancell is at right now lol ... gets a lot into a short time... disappointing Q&A though for which I don't blame Cliff... we will be getting news here especially from Covidity as it is a rapid program but from other parts of the pipeline... I think the appointment of Tear is important for sealing deals.